51. Bicyclic [3.3.0]-Octahydrocyclopenta[c]pyrrolo Antagonists of Retinol Binding Protein 4: Potential Treatment of Atrophic Age-Related Macular Degeneration and Stargardt Disease
- Author
-
Boglarka Racz, Keith D. Barnes, Enrique Michelotti, William H. Martin, Emily Freeman, Nicoleta Dobri, Christopher L. Cioffi, Charles L. Cywin, Douglas G. Stafford, Konstantin Petrukhin, Lei Zhu, Douglas B. Kitchen, Michael Conlon, Ping Chen, Paul G. Pearson, Daniel Schwarz, and Graham Johnson
- Subjects
genetic structures ,Pharmacology ,Article ,Madin Darby Canine Kidney Cells ,Rats, Sprague-Dawley ,Bridged Bicyclo Compounds ,Macular Degeneration ,Structure-Activity Relationship ,chemistry.chemical_compound ,Dogs ,In vivo ,Geographic Atrophy ,Drug Discovery ,medicine ,Animals ,Humans ,Stargardt Disease ,Pyrroles ,Retinol binding protein 4 ,Retinal pigment epithelium ,biology ,Neurodegeneration ,Retinol ,Macular degeneration ,medicine.disease ,eye diseases ,Rats ,Stargardt disease ,Retinol binding protein ,medicine.anatomical_structure ,chemistry ,Biochemistry ,biology.protein ,Molecular Medicine ,Retinol-Binding Proteins, Plasma - Abstract
Antagonists of retinol-binding protein 4 (RBP4) impede ocular uptake of serum all-trans retinol (1) and have been shown to reduce cytotoxic bisretinoid formation in the retinal pigment epithelium (RPE), which is associated with the pathogenesis of both dry age-related macular degeneration (AMD) and Stargardt disease. Thus, these agents show promise as a potential pharmacotherapy by which to stem further neurodegeneration and concomitant vision loss associated with geographic atrophy of the macula. We previously disclosed the discovery of a novel series of nonretinoid RBP4 antagonists, represented by bicyclic [3.3.0]-octahydrocyclopenta[c]pyrrolo analogue 4. We describe herein the utilization of a pyrimidine-4-carboxylic acid fragment as a suitable isostere for the anthranilic acid appendage of 4, which led to the discovery of standout antagonist 33. Analogue 33 possesses exquisite in vitro RBP4 binding affinity and favorable drug-like characteristics and was found to reduce circulating plasma RBP4 levels in vivo in a robust manner (>90%).
- Published
- 2015
- Full Text
- View/download PDF